The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk ...

Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These ...

Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars, used to trea...

Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalm...

Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-rela...

For the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while revenue grew 14 per cent to Rs 7360 ...

The Indian Pharmaceutical Alliance (IPA) and various pharma industry associations in India and other key stakeholders in the pharmaceutical...

The statement further said that the alliance is working closely with the International generic and biosimilar medicines association, the WH...

Biosimilars to biologic drugs are what generics are to chemical drugs.

Ogivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the...

On the BSE, 1.61 lakh shares were traded on the counter so far in the trade.

The USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.

This is Mylan and Biocon's "first US regulatory submission through the 351(k) pathway and reinforces the strength of collaboration."

Mylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statem...

Drug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India.

Drugmakers are set to gain with US’ plan to reduce data exclusivity period to 7 years from 12 years.